Testing effectiveness (Phase 2)Study completedNCT03387475
What this trial is testing
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Who this might be right for
Myelodysplasia
University Hospital, Grenoble 39